Physician profile
Navya Perkit
NPI 1871226217
$1,464.59
in general payments reported to CMS, 2019-2025
15 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $136 · 2023: $480 · 2024: $459 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.26 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $158.35 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Alexion Pharmaceuticals, INC. | $151.09 | 2022-2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $145.21 | 2023-2025 | Opdivo, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $105.85 | 2022-2024 | |
| Eisai INC. | $79.29 | 2024 | |
| Grifols USA, LLC | $61.57 | 2024 | Gamunex-C |
| Alcresta Therapeutics, INC. | $35.45 | 2023 | Relizorb |
| Novo Nordisk INC | $33.93 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $29.03 | 2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $28.83 | 2024 | Jynarque |
| Pfizer INC. | $20.91 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $19.05 | 2025 | Opsumit |
| Amgen INC. | $19.02 | 2024 | Repatha |
| Incyte Corporation | $14.75 | 2024 | Monjuvi, Pemazyre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navya Perkit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.